Astellas Pharma Competitors and Similar CompaniesClear all
Astellas Pharma's competitors and similar companies include Pfizer, Bayer, Urovant Sciences and Viatris.
 Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. |  Viatris Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products. | ||
Founding Date | Founding Date 1923 | Founding Date 1849 | Founding Date 1863 | Founding Date 2016 | Founding Date 2020 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Bentley, AU Footscray, AU Mulgrave, AU Sydney, AU see more | Locations Irvine, US HQ Basel, CH | Locations Canonsburg, US HQ Carole Park, AU Millers Point, AU Campos Dos Goytacazes, BR São Paulo, BR Sofia, BG Toronto, CA see more | |
Employees | Employees 14,754 | Employees 88,0006% increase | Employees 92,8152% decrease | Employees 3950% increase | Employees 38,0003% increase |
Valuation ($) | Valuation ($) 20.8 b | Valuation ($) 163.9 b | Valuation ($) 27.1 b | Valuation ($) N/A | Valuation ($) 14 b |
Financial | |||||
Revenue (est.) | Revenue (est.) ¥1.6t (FY, 2024) | Revenue (est.) $63.6b (FY, 2024) | Revenue (est.) €46.6b (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $14.7b (FY, 2024) |
Cost of goods | Cost of goods ¥134.6b (FY, 2024) | Cost of goods $17.9b (FY, 2024) | Cost of goods €12b (FY, 2024) | Cost of goods N/A | Cost of goods $9.1b (FY, 2024) |
Gross profit | Gross profit ¥1.5t (FY, 2024) | Gross profit $45.8b (FY, 2024) | Gross profit €35.8b (FY, 2024) | Gross profit N/A | Gross profit $5.6b (FY, 2024) |
Net income | Net income ¥17b (FY, 2024) | Net income $8.1b (FY, 2024) | Net income (€2.5b) (FY, 2024) | Net income ($146.7m) (FY, 2020) | Net income ($634.2m) (FY, 2024) |
Operating ⚠ | |||||
Countries | Countries N/A | Countries 125 (FY, 2021) | Countries 83 (FY, 2021) | Countries N/A | Countries 165 (Q1, 2023) |
Manufacturing Sites | Manufacturing Sites N/A | Manufacturing Sites 39 (FY, 2021) | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 40 (Q1, 2023) |
For sources of this data, please see the company profile
View Company Profiles
Pfizer
HQ
New York, US
Employees
88,000↑ 6% increase
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View company
Bayer
HQ
Leverkusen, DE
Employees
92,815↓ 2% decrease
Bayer is a life sciences company specializing in healthcare and nutrition.
View companyUrovant Sciences
HQ
Irvine, US
Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions.
View companyViatris
HQ
Canonsburg, US
Employees
38,000↑ 3% increase
Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products.
View company